换一批
第一作者：
Yi,Guo
第一单位：
Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
作者：
关键词
ALIS, amikacin liposomal inhalation suspensionAPI, active pharmaceutical ingredientBALF, bronchoalveolar lavage fluidCOPD, chronic obstructive pulmonary diseasesCS, chitosanDPIs, dry powder inhalersDPPC, dipalmitoylphosphatidylcholineDSPC, 1,2-distearoyl-sn-glycero-3-phosphocholineDa, aerodynamic diametersELF, epithelial lining fluidFDA, US food and drug administrationFDKP, fumaryl diketopiperazineHA, hyaluronic acidIL-4, interleukin-4IL-5, interleukin-5Inhaled sustained release formulationsLABA, long-acting β2-adrenoceptor agonistLPPs, large porous particlesLocal lung diseasesMCE, mucociliary escalatorMDIs, metered dose inhalersMP, mucoadhesive particlesMPP, mucus-penetrating particlesMW, molecular weightMn, number-average molecular weightNLCs, nanostructured lipid carriersPCL, poly-ε-caprolactonePDD, pulmonary drug deliveryPEG, polyethylene glycolPK, pharmacokineticsPLA, polylactic acidPLGA, poly(lactic-co-glycolic acid)PVA, polyvinyl alcoholPharmaceutical strategiesPulmonary clearance pathwaysPulmonary drug deliveryPulmonary exposurePulmonary safetySLNs, solid lipid nanoparticlesSystemic diseasesTmax, time of maximum concentration
DOI
10.1016/j.apsb.2021.05.015
PMID
34522598
发布时间
2021-09-16
- 浏览4
Acta pharmaceutica Sinica. B
2021年11卷8期
2565-2584页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
